Ramucirumab + Pembrolizumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Head and Neck Cancer
Conditions
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
Trial Timeline
Oct 27, 2023 → Jun 30, 2030
NCT ID
NCT05980000About Ramucirumab + Pembrolizumab
Ramucirumab + Pembrolizumab is a phase 2 stage product being developed by Eli Lilly for Recurrent Head and Neck Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05980000. Target conditions include Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05980000 | Phase 2 | Active |
| NCT03650764 | Phase 1/2 | Active |
| NCT02443324 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Head and Neck Cancer